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ABSTRACT 
Tumor-infiltrating lymphocytes (TIL) are crucial for anti-tumor 
immunity. However, regulatory T cells (Treg) often accumulate in tumor 
tissue and are able to reduce both lymphocyte activity and 
transendothelial migration and thereby reduce the local anti-tumor 
immunity. The aim of this thesis was to investigate the anti-tumor 
immune response in intestinal tumors in vivo with a special emphasis on 
Treg function and lymphocyte recruitment. First, the APCMin/+ mouse 
model of intestinal tumors was used to investigate tumor-associated 
lymphocyte subsets and their modes of accumulation into intestinal 
tumors. We could show that the tumors of APCmin/+ mice harbour an 
increased number of Treg, which was also confirmed in human colon 
cancer and colon adenomas. Furthermore, a decrease of conventional T 
cells was observed. 
By breeding APCmin/+ mice with DEREG mice, which harbour a high 
affinity diphtheria toxin receptor under the control of the FoxP3 
promoter, we were able to deplete Treg in tumor-bearing mice.  Treg 
depletion resulted in an accumulation of effector T cells in the intestinal 
tumors, as a consequence of both higher proliferation and increased 
migration into the tumors. Furthermore, an increase of the Th1 
associated chemokine receptor CXCR3 on T cells and increased levels of 
IFN-γ was found in the absence of Treg. One important mechanism for 
TIL migration in the absence of Treg was the increased secretion of the 
CXCR3 ligands CXCL9 and 10. We could also demonstrate that CXCR3 
is crucial for migration into intestinal tumors.  
In conclusion, this thesis demonstrates that Treg inhibit a Th1 associated 
anti-tumor response in intestinal tumors partly by reducing effector T cell 
accumulation. Strong Th1 responses have been correlated to improved 
patient outcome in colon cancer. Therefore, the results of this thesis 
indicate that eliminating Treg or reducing their suppressive mechanisms 
would constitute a viable anti-tumor therapy, not only increasing effector 
T cell activity but also their recruitment into tumors.  
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SAMMANFATTNING PÅ SVENSKA 
En av de vanligaste cancerformerna i västvärlden är koloncancer, vilken 
ger upphov till en stor andel av alla cancerrelaterade dödsfall. De 
vanligaste riskfaktorerna för att utveckla koloncancer kan alla kopplas till 
den västerländska livsstilen, främst fetma, alkohol, tobak och en diet med 
mycket rött kött, fett och för lite frukt och fibrer. Något som däremot 
kan motverka de negativa följderna av en yttre livsstilspåverkan är 
kroppens immunförsvar där effektor T-celler, både cytotoxiska T-celler 
och T-hjälparceller, har en viktig roll för att bekämpa tumörcellerna. Men 
för att kunna döda cancer cellerna måste T-cellerna kunna ta sig in i 
tumören. En annan form av T-celler, regulatoriska T-celler (Treg), 
kontrollerar normalt att immunförsvaret inte överreagerar. I flera olika 
typer av cancer har det påvisats höga nivåer av Treg i tumörerna och man 
tror allmänt att detta kan ge ett minskat anti-tumörförsvar vilket då 
gynnar tumörtillväxten. I denna avhandling har vi därför undersökt Tregs 
påverkan på immunförsvaret i tumörer från tarmen för att förstå deras 
inverkan på rekrytering och funktion hos effektor T-celler. 
APCmin/+ möss utvecklar spontant tumörer i hela tarmsystemet på grund 
av en mutation i apc supressorgenen. Sådana mutationer initierar 
tumörutveckling också i en majoritet av alla humana koloncancer 
patienter. I tumörerna hos APCmin/+ möss upptäcktes en ansamling av 
Treg jämfört med närliggande normal tarmvävnad. En liknande 
ansamling bekräftades även i humana koloncancerprover och i humana 
adenom, ett förstadium till invasiva tumörer. Vidare var även effektor T-
cellerna påverkade i mustumörerna, med lägre andel celler än i den 
normala tarmvävnaden. Detta indikerar att immunförsvaret är reducerat i 
tarmtumörer och att detta kan öka tumörtillväxten. Denna musmodell 
har i denna avhandling påvisats besitta specifika immunologiska skillnader 
enbart i tumörer som liknar de i human koloncancer och har därför 
vidare i arbetet använts som en modell för koloncancer. 
För att undersöka om ansamlingen av Treg i tumörerna påverkar 
immunförsvaret introducerades DEREG-möss i vår APCmin/+ avel. 
DEREG-möss gör det möjligt att selektivt eliminera Treg med 
difteritoxin, då dessa möss har en receptor för difteritoxin uttryckt bara 
på Treg. Med hjälp av dessa APCmin/+/DEREG-möss möjliggjordes 
studier av hur tumörernas immunförsvar påverkas i frånvaro av Treg. När 
Treg eliminerades noterade vi en ökning av effektor T-celler i tumörerna. 
En ökning av T-celler i tumörvävnaden kan ha flera olika orsaker, ökat 
inflöde, ökad celldelning eller större benägenhet att stanna i tumören. T-
celler delade sig i högre utsträckning i frånvaro av Treg vilket delvis kan 
ha påverkat det ökade antalet. För att undersöka om T-cellerna dessutom 
lyckades ta sig in i tumören bättre i avsaknad av Treg, gjordes 
migrationsexperiment där inmärkta celler injicerades i tumörbärande 
möss och frekvensen av migrerande celler in i olika organ undersöktes. 
En större andel T-celler tog sig in i tumören när Treg var borta vilket 
därmed också påverkade den högre frekvensen av T-celler i avsaknad av 
Treg. Därmed visar detta arbete att Treg kan minska ett effektiv anti-
tumör försvar bestående av T-celler genom att både hämma T-cell 
migration in i tumören och även deras tillväxt.  
För att kunna migrera in i tumörer behöver T-celler signaler som leder 
dem rätt, så kallade kemokiner. CXCR3 är en kemokinreceptor som sitter 
på T-celler associerade med ett effektivt anti-tumörförsvar. Vi kunde visa 
att CXCR3 är nödvändig för T-cellernas migration in i tarmvävnaden och 
specifikt till tumörer. T-celler med denna receptor var få i tumörerna, 
men när Treg eliminerades ökade frekvensen av CXCR3+ T-celler i 
tumören. De kemokiner som binder till CXCR3, CXCL9 och CXCL10, 
var också de som ökade i tumören när Treg var borta. En specifik ökad 
produktion av CXCL10 från endotelceller i tumören kunde också ses i 
frånvaro av Treg. Detta indikerar att Treg påverkar denna rekryteringsväg 
för att undvika att effektiva T-celler migrerar in i tumören. 
Sammanfattningsvis, Treg ansamlas i tumörer och hjälper där till med att 
minska immunförsvaret mot tumören. Att eliminera Treg eller påverka 
deras supressiva funktioner skulle därför kunna bli en effektiv 
immunterapi mot koloncancer. 
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APC Adenomatous polyposis coli  
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CTL Cytotoxic T lymphocyte 
DC Dendritic cells 
DEREG Depletion of regulatory T cells 
DT Diphtheria toxin 
ER Endoplasmic reticulum 
FAP Familial Adenomatous Polyposis 
FC Flow cytometry 
GALT Gut-associated lymphoid tissue 
GI Gastrointestinal  
HEV High endothelial venules 
HUVEC Human umbilical vein endothelial cells 
i.p. Intraperitoneal 
IDO Indoleamine 2,3-dioxygenase 
IEL Intraepithelial lymphocytes 
IF Immunofluorescence 
LP Lamina propria 
LPL Lamina propria lymphocyte 
MAdCAM-1 Mucosal addressin cell adhesion molecule-1 
MHC Major histocompatibility complex 
min Multiple intestinal neoplasia 
MLN Mesenteric lymph node 
NK cells Natural killer cells 
NKT cells Natural killer T cells 
PD-1 Programmed cell death protein-1 
PD-L1 Programmed cell death protein-ligand 1 
PNAd Peripheral lymph node addressin 
PP Payers patch 
pTreg Peripheral induced Treg 
RT-PCR Real time PCR 
TCR T cell receptor 
TIL Tumor infiltrating lymphocytes 
TRAIL TNF-related apoptosis-inducing ligand 
Treg Regulatory T cell 
tTreg Thymus derived Treg 
WT Wild-type 
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INTRODUCTION 
Brief introduction to the immune system  
All living organisms are constantly exposed to pathogens, bacteria, 
viruses and foreign substances. The immune system is a crucial player to 
defeat invaders and to keep a balanced reaction. It comprises an intricate 
organisation of cells and organs that protect its host against pathogens 
and can be divided into innate or adaptive immunity.  The innate immune 
system is the first response that is always present to defeat an intruder. It 
consists of both the epithelial border creating a physical barrier but also 
phagocytes, antigen presenting cells (APCs), and proteins of the 
complement system1. Adaptive immunity consists of lymphocytes 
recognizing antigens on infectious agents and provides a secondary 
response when innate immunity is insufficient. This is a much stronger 
and specialized response that provides a memory for future infections2.  
Lymphocytes arise from stem cells in the bone marrow and further 
mature in either bone marrow for B cells or thymus for T cells. Naïve 
lymphocytes leave their generative lymphoid organ and circulate between 
the blood and peripheral lymph nodes where they can encounter APCs 
that present antigens from digested microbes.  If naïve lymphocytes 
encounter their antigen and receive stimulation from APCs a 
differentiation into effector cells or memory cells occurs2.  
The course of an infection usually starts with an infectious microbe 
penetrating the epithelial border such as the gastrointestinal (GI) tract or 
the skin to invade the host. The first response is the innate immunity 
where phagocytes, including neutrophils and monocytes ingest the 
microbes in order to neutralize them, cell death initiated by Natural killer 
(NK) cells and cytokines secreted by APCs, such as macrophages and 
dendritic cells (DC) to initiate inflammation and a lymphocyte response. 
DC capture protein antigens and process them in order to display 
peptides bound to Major histocompatibility complex (MHC) on the 
surface and migrate into peripheral lymph nodes to activate the adaptive 
Regulatory T cells and lymphocyte migration into intestinal tumors 
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immunity. Two MHC complexes exist, MHC I and II. The peptides 
presented by MHC class I molecule are generated in infected cells by 
proteasome-mediated protein degradation in the cytosol and transported 
into the endoplasmic reticulum (ER) where they will bind to MHC class I 
molecules3. Infected cells can also phagocytose antigens leading to 
peptides residing in endosomes that can be presented by MHC class II, 
assembled in the ER4. 
Co-stimulatory molecules on the APCs and secreted cytokines enable T 
cells to proliferate and differentiate into effector cells, either T helper 
(Th) cells or cytotoxic T lymphocytes (CTL) and these can then be 
transported through the circulation to the site of infection5. T cells 
exhibit different ways of combating the microbe, Th cells secretes 
cytokines in order to activate innate cells to phagocytos microbes and to 
kill infected cells, while CTL kills infected cells in a cell-contact 
dependent manner6. B cells are also activated in peripheral lymph nodes 
but will need help from Th cells to gain full response.  Differentiated B 
cells are called plasma cells and secretes antibodies that bind to 
extracellular microbes and prevent them from infecting host cells, 
promoting their ingestion and destruction7. When a pathogen is 
eliminated, the majority of activated lymphocytes die by apoptosis and 
the immune system returns to homeostasis8. However, memory cells 
remain for a long period of time and respond rapidly in case the same 
pathogen invades the host again9.  
Gastrointestinal tract 
The GI tract is an intricate organ system involved in food transportation 
and uptake, and is in constant contact with the environment10. The 
anatomy of the GI tract consists of all structures involved in the process 
from food intake to waste, with the main parts being stomach, small 
intestine and colon10. Not only is the GI tract part of absorptive, digestive 
and secretory processes but also an intricate part of the host defence 
against foreign antigens and pathogens11. A mucosal surface throughout 
the GI tract forms a barrier between the host and the environment and 
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consists of one layer of epithelial cells and the underlying lamina propria 
(LP). The epithelium consists of mainly absorptive enterocytes but also 
antimicrobial peptide-secreting Paneth cells, mucus producing goblet 
cells, neuroendocrine cells12 and intraepithelial lymphocytes (IEL). The 
LP consists of mainly connective tissue that supplies the mucosa with 
blood vessels, lymphatic drainage and nerves but also many different 
types of immune cells. In the small intestine the mucosal surface forms 
villi that stretch out into the lumen and to further increases the surface 
area microvilli are present on epithelial cells. The crypts between villi 
contain the stem cells that give rise to the different types of mature 
epithelial cells13.  
  The intestinal mucosa consists of one layer of epithelial cells and the Figure 1.
underlying lamina propria. The small intestine contains villi that stretches out into the 
lumen while the colon present a smooth surface with crypts.  IEL: Intra epithelial 
lymphocytes, LPL: lamina propria lymphocytes, MLN: Mesenteric lymph node.   
The small intestine receives digested food from the stomach and further 
digests it into disaccharides, peptides and fatty acids and absorbs the 
nutrients. Liquid residue and non-digestive material continue into the 
colon, which main function is to reabsorb water released in the small 
intestine14. The colon contains more bacteria than there are cells in the 
entire human body. Non-pathologic bacteria are called commensals as 
they live in symbiosis with the host and exert help with synthesizing 
vitamins and digesting polysaccharides in pathways that humans lack 
IELIEL
Peyers
patch
MLN
Epithelial cells
Lamina propia
M 
cell
Small intestine Colon
LPL
LPLLPL
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enzymes for15. The colon do not form villi and instead form a smooth 
surface with crypts like the small intestine, however lacking Paneth cells10.   
Due to the constant interaction between host and environment the GI 
tract needs several barrier mechanisms to protect from foreign bacteria 
and substances16, such as the chemical barrier of anti-bacterial peptides 
secreted by paneth cells17 and the physical barriers of epithelial cells and 
mucin, secreted by goblet cells, which creates a mucus layer reducing the 
direct contact between lumen and epithelium10. To discriminate between 
pathogenic agents, commensal bacteria and food nutrients the immune 
system is important. Through oral tolerance APCs and T cells exert a 
state of unresponsiveness towards non-pathogenic antigens in the 
intestine18.  In the absent of a danger signal homeostatic gut APCs 
migrate to the lymph nodes where they contribute to the oral tolerance 
against gut content19.  
Gut-associated lymphoid tissue (GALT) is a network of highly organized 
immune structures in the intestine and consists of Peyer´s patches (PP), 
appendix and isolated lymphoid follicles. PP are lymphoid follicles 
residing in the small intestine and are responsible for T cell priming20. 
Some of the epithelial cells covering PP are M cells that transport 
antigens from the lumen into the PP and to the APCs21. Mesenteric 
lymph nodes (MLN) are another major site of antigen presentation22 and 
oral tolerance induction in the gut23. Together with the gut draining 
MLN, GALT provides antigen sampling from the entire GI tract to 
optimize opportunities for naïve lymphocytes to encounter antigens and 
thereby activate them or induce tolerance24. The effector cells can 
thereafter exit GALT and MLN via efferent lymphatic and enter the 
systemic circulation to home to the gut to exert their effector functions25.  
Intestinal lymphocytes  
The majority of the human body’s lymphocytes reside in the intestine and 
have an important task to balance the constant interaction of microbes, 
both pathogenic and commensals in the lumen26. The immune cells in the 
intestine are mainly present in two major sites, the GALT where initial 
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antigen presentation to adaptive immunity cells takes place and the LP 
and epithelial layer where effector functions are executed11. IEL residing 
in the epithelial layer, are antigen experienced T cells that balance a 
protective immunity while keeping the integrity of the epithelial barrier27.  
Both cells of innate and adaptive immunity co-exist in the LP11. T cells 
are a major player orchestrating immune responses, both by activation of 
other cells but also by direct killing of foreign pathogens28. Naïve T cells 
leave the thymus as immature T cells with a broad range of T cell 
receptors (TCR) and can be activated in the periphery after antigen 
encounter24. T cell activation requires at least two signals to become 
activated, first TCR engagement with the antigen presented by MHC 
complexes29 and secondly engagement of the co-stimulatory molecule 
CD28 by CD80 and CD86 on APCs30. A third signal includes cytokines 
secretion from the APCs, potentially initiated by adjacent innate immune 
cells31.  
Mucosal T cells form a complex and heterogeneous population of 
lymphocytes, which are all antigen experienced but have a wide repertoire 
of antigen recognition and mode of action10,11. Several different effector T 
cells exist and they are commonly divided into CD4+ Th cells and CD8+ 
CTL2. CD4+ Th cells mediates a response in inflammation, 
autoimmunity, asthma, allergy and tumor immunity2,16 and their TCR are 
able to bind to MHC class II4. Th cells can be further divided into 
different subsets depending on cytokine secretion and transcription 
factors28. The differentiation pathway of an individual T cell is dependent 
on the cytokine milieu during activation31. The different subsets have also 
been shown to be plastic leading to a possibility of evolvement of subset 
depending on the cytokine milieu24. Another CD4+ subset is the 
regulatory T cell (Treg) that regulates and maintains self-tolerance and 
can supress other T cells in order to control immune responses32. CTL on 
the other hand are CD8+ T cells that can kill infected cells by releasing 
perforin and granzymes33 and by Fas-FasL interaction34.  
Regulatory T cells and lymphocyte migration into intestinal tumors 
6 
                   
 Differentiation of naïve T cells into different subsets is dependent on Figure 2.
cytokine milieu.  
Th1 cells 
Th1 cells are critical for cell-mediated immune responses against 
intracellular pathogens and tumor cells35, and are characterized by 
secretion of IFN-γ and IL-2 and expression of the transcription factor T-
bet28. A cytokine milieu consisting of IL-12, TNF-α and IFN-γ followed 
by activation of the transcription factor STAT1 and STAT4 induces Th1 
cell differentiation28,36. Activation by IL-12 increases IFN-γ expression 
through STAT1 signalling to induce the transcription factor T-bet. This 
further increases the signature cytokine IFN-γ expression in a positive 
feedback loop28.  
IFN-γ is a cytokine mediating innate and adoptive immunity against both 
viral and bacterial infections and tumors37. The main functions of IFN-γ 
signalling are regulation of host defence, immune system, cell cycle, 
apoptosis, inflammation and cell proliferation37-39 but also maintenance of 
the intestinal epithelial barrier integrity40. IFN-γ produced by Th1 cells 
can activate macrophages to phagocytose and digest intracellular bacteria 
and stimulate the microbicidal activities of phagocytes thereby promoting 
the intracellular destruction of phagocytosed microbes41. IFN-γ can also 
supress T cell differentiation into Th2 and Th17 cells24,42 creating a 
favourable milieu for Th1 cells.  
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Th2 cells 
Th2 cells are responsible for humoral-mediated immunity against 
extracellular parasites but also eosinophilic inflammation involved in 
allergies and atopic illnesses28,43. Their main functions are to enhance 
barrier mechanism and expulsion and/or killing of parasites. IL-4 and IL-
2 are primarily accountable for the differentiation of Th2 cells through 
transcription factors STAT6 and GATA-343. Th2 cells mediate their 
functions by secretion of IL-4, IL-5, IL-9 and IL-13 and often in 
epithelial tissues in the intestinal tract and lungs44.  
Th17 cells 
Th17 cells are a pro-inflammatory T cell subset defined by secretion of 
IL-17 and expression of the transcription factor ROR-γt45. Th17 cells are 
important in host defence against extracellular bacteria and fungi but are 
also involved in tissue inflammation and autoimmunity46. The signature 
cytokines of Th17 cells are IL-17A, IL-17F, IL-22, IL-6 and TNF-α. 
Differentiation of Th17 cells is induced by cytokines IL-6, TGF-ß and 
IL-1β while IL-23 provides maturation, expansion and pathogenicity for 
Th17 cells45,47,48.   
ROR-γt induces transcription of the IL-17α gene, allowing production of 
IL-1745 which is a pro-inflammatory cytokine49. In the gut IL-17 
promotes epithelial barrier functions by stimulating tight junction protein, 
microbial peptides and mucin secretion50. Secretion of IL-17 leads to 
recruitment of neutrophils, activation of innate immune cells, enhanced B 
cell function and release of pro-inflammatory cytokines TNF-α, GM-
CSF, and IL-1ß28.  
Pro-inflammatory Th17 cells can be re-programed in the gut to take on a 
regulatory function. These cells secrete less pro-inflammatory cytokines 
and exert their suppressive capacity by secretion of IL-10, TGF-ß and 
expression of CTLA451. In the presence of IL-6, Treg can be converted 
into a Th17 cell and even regulatory IL-17+FoxP3+ cells have been 
observed in colitis52. In light of this, Th17 can have both a pathogenic 
and a tissue-protective role in the intestine48.  
Regulatory T cells and lymphocyte migration into intestinal tumors 
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Regulatory T cells 
Treg is a CD4+ T cell subset involved in maintaining immune 
homeostasis, preventing autoimmunity and limiting immunopathology53. 
Development and maintenance of Treg is dependent on IL-2, IL-10 and 
TGF-ß54,55. Treg are usually identified as expressing the transcription 
factor forkhead box P3 (FoxP3), which is considered as the “master 
regulator” of Treg development and function56-58. Treg lacking FoxP3 
have been found in autoimmune diseases, however they are not as potent 
suppressors as FoxP3+ Treg59. Other markers used to distinguish Treg are 
CD25, CTLA-4, GITR, Programmed cell death protein-ligand 1 (PD-L1), 
CD127low and Nrpl-160,61, however neither marker is unique for Treg. 
CD25, the α-chain of the IL2 receptor32,  was the first marker used to 
identify T cells that were able to supress autoimmunity57, but has since 
then also been reported to be expressed on activated conventional T cells 
in humans62. CTLA-4, a co-inhibitory molecule and GITR, a co-
stimulatory molecule is expressed on both Tregs and activated T cells63 
and are therefore not unique Treg markers62,64. CD39 has gained 
interested as a new functional Treg marker65, however only in mice all 
Tregs express CD39 while in humans only a fraction of Tregs express 
CD3966.  
Two subsets of Tregs exist, thymus derived Treg (tTreg) and peripherally 
induced Treg (pTreg)67. pTreg are induced in the periphery in response to 
environmental signals from tumors, infections and other pathological 
inflammatory conditions65,68 where mucosal sites are known to be a 
preferential site for peripherial induction69. While tTreg only need TCR 
engagement and IL-2 signalling to develop, pTreg need additional 
signalling such as TGF-ß and retinoic acid. The ability to differentiate 
between these two subset is however difficult since no specific marker 
has been identified70.  
Treg migrate to both sites of inflammation and the draining lymph nodes 
during an immune response71 and supress effector cells such as Th1, Th2, 
Th17, T follicular cells60, NK cells and natural killer T (NKT) cells56, and 
also induce tolerogenic properties in DC and macrophages72. Several 
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different modes of suppression have been identified for Tregs, including 
cytokine secretion, surface molecule signalling, cytolysis and adenosine 
production73 (Figure 3). Treg have the ability to supress via cell contact-
independent mechanisms by production of the inhibitory cytokines71 IL-
10, IL-35 and TGF-ß, which regulates proliferation and cytokine 
production of both Treg and conventional T cells73. IL-10 secretion can 
down-regulate pro-inflammatory cytokine production and expression of 
co-stimulatory molecules on APCs, which decreases T cell activation and 
differentiation56. TGF-ß inhibits cytotoxic activity of NK cells, 
macrophages and CD8+ T cells and inhibit proliferation and 
differentiation of effector T cells74. IL-35 is secreted by Tregs, non-
effector cells75 and tumor cells76 and is able to supress T-cell proliferation 
and effector functions72.   Another mode of action for IL-35 is supressing 
Th17 response and inhibiting differentiation into Th17 cells77.  
Treg can also use cell-cell contact dependent signalling through surface 
receptors, CD2560, CTLA-4 and PD-L1 to supress immunity78. CTLA-4 
inhibits effector T cell activation while PD-L1 regulates on-going 
immune responses73. High expression of the inhibitory molecule CTLA-4 
creates a competition for the co-stimulatory marker CD80/86 on DCs 
and leads to a down regulation of these co-stimulatory molecules and 
reduces T cell activation56,71. CTLA-4 can also increase the TCR signal 
strength required for naïve T cell activation thereby preventing activation 
of T cells by low levels of TCR stimulation79. PD-1 exerts two 
mechanisms of peripheral tolerance, promotion of Treg development and 
inhibition of self-reactive T cells80. PD-L1 expressed on Treg interact 
with PD-1 on T cells, and will cause inhibition of TCR signalling81 leading 
to reduced T cell proliferation, cytokine production and cytolytic function 
and impaired T cell survival82.  Another way Treg could dampen T cell 
activation is by their expression of CD25, which is part of the IL-2 
receptor. IL-2 is crucial for T cell activation, and Treg consumption of 
IL-2 prevent effector T cell access to IL-260 and can result in cytokine 
deprivation induced apoptosis of effector T cells83.  
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 Suppressive mechanisms of Treg.  Figure 3.
Other cell-cell contact mechanism includes cytolysis through secretion of 
perforin and granzyme B, with the ability to kill effector T cells56 and 
APCs73. However, mucosal Treg might not use this mechanism since a 
study has shown absence of granzyme expression in Treg in human 
gastric mucosa84. Generation of the anti-inflammatory mediator 
adenosine from ATP through the ectonucleotidas CD39 and CD73 is 
identified as another way for Treg to supress proliferation and cytokine 
secretion. Binding to the A2A adenosine receptors on effector T cells 
results in increased cAMP levels that inhibit cytokine responses and 
suppresses effector T cells and DCs85,86.  
CD8+ T cells 
Naïve CD8+ T cells give rise to CTL that can eliminate tumor cells and 
cells infected with intracellular pathogens, mainly viruses87. CD8+ T cells 
are able to recognize pathogen-derived peptide complexes on MHC class 
I molecules present on the surface of infected cells. The peptides are 
derived from cytosolic proteins3. In a cell contact dependent manner 
CTLs kill infected cells through two mechanisms, release of cytolytic 
granules or by engaging cell-surface death receptors with both leading to 
apoptosis88. Cytolytic granules released from CTLs contain perforin and 
granzyme A and B. Perforin causes pore-like structures analogous to the 
C9 component of the complement system34 enabling granzyme passage 
into infected cells. Granzymes subsequently induce apoptosis through 
caspase activation33. The death-receptor pathway includes FasL-Fas and 
TNF-α interaction that activates the caspase pathway of apoptosis89. 
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Homing and recruitment  
Lymphocytes circulate in the blood stream in search for their antigen and 
for their site of effector response during a process of recirculation and 
homing14. Migration of naïve T cells from the blood to secondary 
lymphoid tissues occurs through high endothelial venules (HEVs). HEVs 
associated with PPs contain mucosal addressin cell adhesion molecule-1 
(MAdCAM-1) whereas HEVs within MLN express both MAdCAM-1 
and peripheral lymph node addressin (PNAd)25 in order to guide the cells 
to the right location. In the MLN and PPs effector T cells are activated, 
differentiated and imprinted to express specific chemoattractants, 
receptors for endothelial adhesion molecules thus enabling them to 
migrate into the intestine from the circulation14.  
Transendothelial migration into peripheral tissue is an intricate multistep 
process allowing cells to migrate from blood vessels into sites of infection 
and it includes several steps; tethering, rolling, activation, arrest and 
finally transmigration14. Endothelial cells are able to express P- and E- 
selectin during inflammation and will recognize their ligands on 
leukocytes. A weak reversible adherence to the vessel wall will occur 
leading to rolling of the cells. The second step includes integrins 
interacting with adhesion molecules on endothelium slowing down the 
rolling. By stimulation by chemokines, an increased integrin activation 
and strong adhesion to the endothelial cell surface will occur leading to 
firm arrest of the cell on the endothelium. Finally the cell can enter, 
through the endothelium by diapedesis, guided by chemokines90,91.  
Transendothelial migration can however be hampered by suppressive 
mechanisms. Tregs from cancer patients have been found to inhibit in 
vitro transendothelial migration92 and this may be a mechanism to regulate 
an infiltrating immune response. However, the role of Treg in migration 
of lymphocytes in vivo has not been fully investigated and this is a major 
focus in this thesis. 
 
Regulatory T cells and lymphocyte migration into intestinal tumors 
12 
Chemokines play a vital role in mediating migration and homing. 
Chemokines are small (8-10kDA) chemoattractants93 secreted by 
leukocytes, epithelial cells and tumor cells in order to mediate migration 
of immune  cells94. More than 50 chemokines have been identified and 
they are grouped into two major sub-groups, CXC and CC chemokines 
and two smaller families C and CX3C, based on the position of the N-
terminal cysteine residues95. Several chemokine receptors and ligands are 
important for homing into the intestine, some of particular interest have 
been studied in this thesis, CXCR3, CCR6 and CCR9 and their ligands.   
CXCR3/CXCL9, 10, 11 
CXCR3 is a Th1 associated chemokine receptor responsible for recruiting 
T cells to site of inflammatory96. CXCR3 is absent on naïve T cells, but is 
quickly up-regulated after DC induced T cell activation97. CXCR3 is also 
expressed on some Tregs98 and innate cells such as NK and NKT 
cells97,99, plasmacytoid DCs100 and subsets of B cells101. Both Th1 cells and 
CTL traffic into inflamed tissue is associated with CXCR3102. However, if 
CXCR3 is needed for lymphocyte migration into intestinal tumor tissue is 
unknown and this is a question that this thesis will address.  
Ligands of CXCR3 are the three IFN-γ inducible chemokines CXCL9, 
CXCL10 and CXCL1194. In C57BL/6 mice a point mutation introduces a 
stop codon early in the CXCL11 gene leading to CXCL11 deficiency in 
these mice103. In addition to chemotactic migration CXCR3 ligands can 
induce Th1 polarization, CD4+ and CD8+ expansion104, apoptosis, 
regulation of growth and angiogenesis105. Differences in both function 
and mechanism have been found between the different chemokines, for 
instance CXCL9 is completely depended on IFN-γ whereas CXCL10 and 
11 are not. Also the binding affinity to CXCR3 differs among the ligands, 
where CXCL11 has the highest and CXCL9 the lowest102.  
Three different isoforms of CXCR3 exist in humans, CXCR3-A, -B and –
alt. CXCR3-A mediates proliferation, chemotaxis, cell migration and 
invasion while CXCR3-B mediates antiproliferative, angiostatic and pro-
apoptotic effects of the CXCR3 ligands. CXCR3-alt resembles CXCR3-A 
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but displays a different carboxyl terminus and is only able to bind to 
CXCL11. In mice only CXCR3-A exists106.  
CCR6/CCL20 
CCR6 and its sole ligand CCL20 are involved in many autoimmune and 
inflammatory processes such as Rheumatoid Arthritis, Multiple Sclerosis 
and inflammatory bowel disease93. CCR6 is expressed on subsets of DC, 
B cells, memory T cells107, Tregs and Th17 cells52.  A subset of IL17+ 
Tregs is induced from memory CCR6+ T cells52.   
CCL20 attract CCR6-expressing cells by inducing migration107 into 
inflammatory sites but not during homeostasis14. However, the PP 
epithelium constitutively express CCL20 and is involved in recruitment of 
CCR6+ Tregs and Th17 cells10. Th17 cell accumulation in LP is also 
dependent on CCR6/CCL20 signalling51. 
CCR9/CCL25 
CCL25 is expressed by epithelial cells in the small intestine and by 
interaction with CCR9 directs T cells, IgA+ plasma blasts and 
plasmacytoid DC specifically to the small intestine10. When CCR9 binds 
to CCL25 an interaction between Gβγ and PI3 kinase initiates a 
downstream cascade activating AKT kinase, which promotes T cell 
proliferation, anti-apoptosis and regulates intestinal inflammation19,108,109.  
Colorectal cancer 
Colorectal cancer (CRC) is the third most common malignancy 
worldwide110 and is the second largest cause of cancer-related death in 
Europe and USA111,112. CRC can metastasise, which decreases overall 
survival prognosis for the patient. Primary destinations for metastases are 
liver, lungs and lymph nodes113,114. Genetic factors cause approximately 
20% of all CRC110 but the majority of cases are due to sporadic mutations 
and risk factors including obesity, lack of exercise, alcohol, tobacco and a 
western diet with large amounts of red meat and fat and low amounts of 
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vegetables, fruits and fibre115. Microbial infections and inflammation are 
also found to increase the risk of CRC94.   
Tumor progression is a multistep process involving genetic, molecular 
and pathological changes116, driving the transformation from low-grade 
dysplastic adenoma to high grade dysplastic adenoma and ultimately 
carcinoma, transforming normal cells into highly dividing malignant 
cells117.  Cancer cells originate from a normal cell that accumulate driver 
mutations leading to full-blown cancer, which usually harbours 2-8 driver 
mutations118. Mutation of the adenomatous polyposis coli (apc) tumor 
suppressor gene, which is rate limiting and an initiator of CRC 
progression, triggers a majority of human CRC. Loss of apc initiates a 
constant activation of the wnt/ß-catenin pathway leading to formation of 
aberrant crypt foci and adenomas119,120, which are defined as an 
accumulation of highly replicating cells94. The subsequent progression 
into invasive cancer occurs by further mutations in different signalling 
pathways such as K-Ras, PIK3CA, TGFBR1, BRAF, TP53, DNA 
mismatch repair genes, FBXW7, NOTCH, SMAD, PI3 kinase and 
TP53109,121,122. 
 
 Colorectal adenoma-carcinoma sequence Figure 4.
Treatment of CRC consists of surgery, radiation or chemotherapy123. 
Although surgery is the main treatment, radiation and chemotherapy aims 
to improve survival and reduce local recurrence124. However, high dose 
chemotherapy has been shown to have a negative effect on the immune 
system causing neutropenia and lymphopenia125.  
apc KRAS 
Smad2/4
p53genetic mutations:
Normal colon Early adenoma 
and dysplastic crypt
Late adenoma Invasive carcinoma
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Cancer immunology 
The immune editing hypothesis claims that the host immune response to 
a neoplastic transformation can be divided into three phases: elimination, 
equilibrium and escape126,127. The elimination stage occurs early during 
tumor growth where a productive anti-tumor immunity can eradicate 
malignant cells127. In equilibrium stage the expansion of transformed cells 
is held in check by the immune system128. Finally, tumor cells evolve to 
escape the immune response, which enables tumor growth129. Several 
studies show how the progression from adenoma to CRC is accompanied 
by an immune equilibrium turning into escape phase, where Th1 
cytokines decreases130,  and IL-17116 and angiogenesis increases131, which 
are all part of the progression into an aggressive cancer.  
The immune system is not always able to eliminate the malignant cells 
during the elimination stage. This has been formulated as the Matzinger 
danger model were cancer might not appear dangerous to the immune 
system since they initially grow as healthy cells and therefor do not send 
out a distress signal to activate APCs132. Unstimulated APCs continuously 
capture exosomes from living cells and apoptotic bodies and by 
presenting them without co-stimulation tolerance of effector cells will 
occur133. T cells can therefore not be stimulated by APCs when 
encountering tumor associated antigens, leading to anergy or apoptotic 
death making the immune system unable to react towards tumors134.  
Other mechanisms for tumor tolerance include tumor derived 
suppression through cytokine secretion including IL-10 and TGF-ß and 
accumulation of suppressive Tregs and NKT cells134,135. 
After escaping an innate surveillance, tumors can take advantage of their 
genetic instability to evade an adaptive immune response134 by down 
regulation of MHC molecules or tumor antigens136,137, or by secreting 
immunosuppressive cytokines138. Tumors might directly kill lymphocytes 
by expression of apoptosis-inducing cell surface molecules such as 
FasL139. Cancer cells can also express PD-L1 to help them evade an 
immune response by interacting with the PD-1 receptor on T cells140, 
leading to down-regulation of effector functions. A strong correlation 
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between PD-L1 expression on tumors and poor prognosis in several 
cancers such as renal cell carcinoma, cervical carcinoma, pancreatic 
carcinoma, and melanoma141-144 has been observed. 
The interaction between host immunity and cancerous cells is vital in 
tumor progression. For cancer development it is necessary that the tumor 
immune response shift from an immunosurveillance profile in the early 
adenoma stage to an immunosuppressive profile in invasive cancer145.  
Consequently, the immune system has emerged as a crucial compartment 
in tumor progression both as an anti-tumor and pro-tumor agent, and 
extensive research is conducted in this field.  
Tumor infiltrating lymphocytes  
Tumor infiltrating lymphocytes (TIL) are the primary host immune 
response against solid tumors146. Infiltration of CD8+ T cells and CD57+ 
NK cells, as well as a Th1-type immune response are all correlated to 
better prognosis in CRC patients147,148. Through a strong TIL response 
metastasis can also be reduced149. However, tumors can manage to escape 
an immune response by modulating the immune system. Functional T 
cells are indeed found in tumors, however they are usually not sufficient 
to defeat tumors because of insufficient amount of T cells, Treg 
suppression, exhaustion from constant stimulation, tumor cytokine 
secretion or tumor secreted enzyme indoleamine 2,3-dioxygenase (IDO) 
suppression150. 
CD4+ T cells are one of the main effector cells against tumors and can 
eradicate tumor cells through activation and recruitment of other effector 
cells151. By recruitment of NK cells, that directly kills tumor cells, and 
macrophages, which may have an effect on tumor destruction through 
production of reactive oxygen/nitrogen species, CD4+ T cells can 
contribute to tumor defence152. CD4+ T cells can also exert a direct anti-
tumor effect by secretion of cytokines or by inducing tumor cell death by 
TNF-related apoptosis-inducing ligand (TRAIL)153 or Fas/Fas ligand 
pathway154. Th1 cells in particular are essential for tumor rejection 
through several different ways, priming of CD8+ cell151, activation of 
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innate antitumor cells151,152,155 and recognition of antigen on MHC class II 
on tumor cells leading to production of cytokines that prevent tumor 
growth or induce tumor cell death152. Thereby is a strong Th1 response in 
CRC associated to prolonged diseases free survival.  A Th17 response is 
on the other hand associated to poor prognosis148 possibly by 
contributing to an increased inflammation.  
Tumors can express MHC class I and are therefore likely to be attacked 
by CD8+ cells151. CD8+ T cells are crucial in anti-tumor immunity through 
direct killing by cytotoxic release of granzyme B and perforin and 
induction of NK cells and innate immune cells156. In order to evade an 
immune response, cancer cells can down regulate the MHC class I to 
avoid a CD8+ T cells137 and also CD1D NKT cells responses136. However 
by secretion of IFN-γ from Th1 cells MHC expression is upregulated on 
tumor cells making them more susceptible for T cell recognition157.    
In colon cancer and many other cancer forms, such as ovarian, lung, 
breast, pancreatic, hepatocellular, head and neck, prostate, and anal 
carcinoma, an accumulation of Tregs is found146. An increased Treg 
frequency in the periphery in later stages of CRC has also been 
observed117,158. However, it is not known if Treg frequencies are increased 
already during early adenoma formation. The role of Treg in most solid 
sterile tumors, such as ovarian and pancreatic hepatocellular is pro-
tumorigenic helping the tumor evade an immune response by supressing 
an immune attack159. However, in CRC it is still under debate whether the 
accumulation of Tregs is related to a good146,148,160-162 or bad60,159,163 
prognostic outcome for the patient.  
Treg can supress protective anti-tumor immune responses and thereby 
help the tumor escape an effective immune attack164. One way Treg can 
help the tumor to avoid a strong immune response is by down-regulating 
the lymphocyte migration into the tumor92 or suppress otherwise potent 
T cells, NK cells and DC effector cells96. Whether this is also true for 
intestinal tumors is investigated in this thesis. In the intestine a constant 
interaction with bacteria and the environment is in place leading to an 
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inflammatory milieu for tumors to grow in. Since Treg can control cancer 
associated inflammation in an IL-10 dependent manner an accumulation 
of Tregs might be beneficial for the host during the early stages of tumor 
formation165. However, studies have shown that Treg can shift into an 
pro-inflammatory cell secreting IL-17 instead of IL-10 and thereby create 
a more inflammatory milieu helping the tumor to grow166. This shift into 
a pro-inflammatory cell could be one reason for why Treg can be both of 
good and bad prognostic outcome for the patient, depending on 
cytokines secreted. 
Recently, Saito et al. proposed a model where FoxP3+ T cells in colorectal 
tumors can either be non-suppressive FoxP3low T effector cells or 
suppressive FOXP3high Tregs and their proportions define the prognostic 
value since FoxP3low cells can supress tumor formation. Accordingly, 
CRC can be divided into type A and type B where type B have a higher 
frequency of FoxP3low cells, presumably effector cells, and therefore a 
better patient survival167.   
Chemokines in cancer 
Chemokines may promote anti-tumor immunity through lymphocyte 
migration or could act as tumor growth factors by increasing tumor 
metastasis, angiogenesis and tumor cell proliferation168,169.  
CXCR3 has a dual role in tumor progression, either by favouring tumor 
growth and metastasis when expressed on cancer cells, as observed in 
glioma170, osteosarcoma171 , breast cancer172 and CRC173  or by limiting 
tumor growth by enhancing anti-tumor immunity when expressed on 
effector cells. CXCR3 is required for optimal generation of IFN-γ 
secreting Th1 cells174 and are thereby an crucial part of anti-tumor 
immunity. In humans, the three different isoforms of CXCR3 exert 
different effects on tumor immunity and affect patient survival. The 
relative expression of CXCR3-A and B isoforms on tumor cells might be 
important in regulating tumor proliferation and survival106. CXCR3-A 
expression on breast172,175 and glioma170 tumor cells is associated with 
increased metastasis and poor survival, while CXCR3-B expression is 
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associated with reduced invasion and growth176,177. Depending on which 
isoform expressed by tumor cells, CXCR3 expression could be of 
positive or negative prognostic value.  
Lack of the CXCR3 ligands CXCL9 and CXCL10 has been associated 
with limited infiltration of T cells into tumors178,179. In several different 
mouse studies expression of CXCL10 in tumor tissue leads to increased 
tumor-specific T cell infiltration and increased survival180,181 and in this 
thesis we will also extend these studies and investigate the effect of these 
chemokines in intestinal tumors. In human breast cancer, however, 
CXCL10 expression is associated with increased frequencies of CXCR3+ 
Tregs175.  CXCL9, 10 and 11 are thought to participate in anti-tumor 
immunity by blocking tumor angiogenesis182-184 and by recruiting Th1 
cells, CD8+ T cells and NK cells. However, these chemokines have also 
been observed to be involved in metastasis104. Furthermore, CXCL10 has 
also been shown to reduce tumor progression both by increasing the 
apoptotic rate of cancer cells185 and by inhibiting endothelial cell 
proliferation independently of CXCR3186.  
Several other chemokines are also involved in tumor progression. CCL22 
helps tumors to escape an anti-tumor response by accumulation of Tregs 
in tumor tissue187,188 and by metastasis of colon cancer111. CCR6 recruits 
macrophages and stimulates epithelial proliferation helping the tumor 
grow93 and CCR9 is thought to be involved in tumor chemoresistance 
and metastasis189.  
Mouse models of colon cancer 
In order to investigate CRC in vivo the use of mouse models have 
emerged. As previously described, CRC results from a cascade of genetic 
changes and mutations and several of them have been pinpointed as 
important steps in tumor progression. Mutation in the tumor suppressor 
apc gene is the earliest alteration in the genesis of CRC and is found 
already in the first stage of CRC, the formation of aberrant crypt foci16. In 
human 85% of all CRC have mutations in the apc gene112, both in 
sporadic cases but also in hereditary disease such as Familial 
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Adenomatous Polyposis (FAP), an autosomal, dominant disease caused 
by truncation of the apc gene190. Therefore, the use of apc mutations in 
mice is well established in order to investigate intestinal tumors. The 
most used model is the APCmin/+ mice but several other exist, such as 
ApcF/wt mice, harbouring a Cdx2-Cre transgene with tumors primarily in 
the colon121, apcΔ468 with systemic inflammation191 and apc+/1638N 
reassembling FAP with other extraintestinal manifestations120.  
APCmin/+mice 
The APCmin/+ model was developed by Moser et al. almost 30 years ago192 
as a mouse model of intestinal adenomas. APCmin/+ mice harbour a 
multiple intestinal neoplasia (min) mutant allele of the apc gene, and loss 
of the remaining normal apc allele leads to continuous wnt signalling. In 
the normal setting, wnt signalling is controlled by wnt initiators and 
inhibitors (Figure 5). When wnt signalling is resting, the apc protein 
forms a complex with several other molecules, which destabilize and 
degrades ß-catenin.  However during wnt signalling the complex can´t be 
formed and ß-catenin can translocate into the nucleus and activate 
transcription of genes involved in cell proliferation such as cyclin-D1 and 
c-Myc16,193. 
  
 wnt signaling in the absences of wnt molecules and during ongoing signaling.  Figure 5.
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APCmin/+ mice develop approximately 15-30 adenomas194 throughout the 
small intestine mostly in the ileum, but colonic tumors are also present93. 
Besides tumor growth in the intestine, the apc mutation in these mice 
causes impairment of development and differentiation in proliferative 
tissues such as the reproductive tract, and in the hematopoietic and 
lymphoid system195. Because of extensive splenic haematopoiesis 
APCmin/+ mice have enlarged spleens93 and anaemia as tumorogenesis 
progresses195. Furthermore, splenic lymphoid follicles and PP are 
diminished in these mice195. Female APCmin/+ mice can also develop 
tumors in the mammary glands196.  
 
 Small intestine of APCmin/+ mice. A. Intestine from an 18-week-old APCmin/+ Figure 6.
mouse.  Arrows indicate tumors. B Hematoxylin staining of small intestine from an 
APCmin/+ mouse. T indicates a tumor.  
Several studies have been conducted on these mice and have helped 
expand the knowledge of tumor progression in the intestine. An 
important role for the gut microbiota in cancer progression has been 
found, where germfree APCmin/+ mice exhibit lower tumor numbers and 
smaller spleens. Increased intestinal permeability is seen in APCmin/+ mice 
and might therefore help the bacteria to accelerate tumor growth197. The 
immune system is partly characterized in these mice and a lymphocyte 
accumulation in the tumors are found consisting of T cells which are 
mainly Tregs164. A further characterisation is conducted in this thesis. In 
the epithelium, CD3+ IEL are increased and express a reduced 
cytotoxicity, which might possibly help promote tumorgenesis198. Also 
the importance of cytokines in CRC development has been found in 
these mice, were for instance IFN-γ signalling is a rate-limiting step in the 
development of adenocarcinoma37 and IL-17 instead promotes tumor 
development199.  
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AIM 
In order to defeat intestinal tumors a strong anti-tumor response is 
needed. However, previous studies have shown that this response can be 
hampered by various suppressive mechanisms. The aim of this thesis was 
to investigate how an effective T cell response can accumulate in 
intestinal tumors and define the role of regulatory T cells as a suppressor 
of anti-tumor immunity.  
Specific aims:  
- Determine the suitability of APCmin/+ mice as an in vivo 
model to study immune responses in intestinal cancer. 
- Define the role of Treg in lymphocyte accumulation and 
migration into tumors. 
- Investigate the importance of Th1 associated chemokine 
receptor CXCR3 in lymphocyte migration into tumors.  
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MAIN METHODS 
APCmin/+ and DEREG mice 
APCmin/+ mice on a C57BL/6 background with a mutation in the apc gene, 
resulting in intestinal tumor formation were used in this thesis in order to 
investigate lymphocyte migration and distribution during tumorgenesis as 
a model for colon cancer.  
In order to investigate Treg in intestinal tumors depletion of regulatory T 
cells (DEREG) mice where used since they enable selective depletion of 
Tregs.  DEREG mice are a bacterial artificial chromosome (BAC) 
transgenic mouse line that carries a DTR-eGFP transgene under the 
control of the FoxP3 promoter, which allows Tregs to be depleted by 
diphtheria toxin (DT) injections. Rodents have very low affinity DT 
receptors compared to humans and are less susceptible to DT induced 
cell death. However, BAC transfection does not cause a complete genetic 
shift such as knock-in mice. Hence only 95-98% depletion of Tregs 
occurs in DEREG mice. Another drawback with DEREG mice is that 
the depletion is only temporary since transgene negative FoxP3+ Tregs 
starts to appear within a week after depletion200.   
APCmin/+ males were bred together with DEREG females to generate 
APCmin/+/DEREG and APCmin/+ mice for paper II and III. A second 
breeding with APCmin/+ males and wild-type (WT) females generated 
APCmin/+ and WT mice for paper I.  At weaning the mice were genotyped 
for the apc mutation by PCR of the tail tip and blood was taken for typing 
of GFP+ Tregs by flow cytometry (FC) to identify DEREG type.  
In vivo Treg depletion 
FoxP3+ Tregs in APCmin/+/DEREG mice were transiently depleted by 
intraperitoneal (i.p.) injections of 0,5 mg DT at four time points, day 1, 2, 
8 and 9 (Figure. 7). Control APCmin/+ mice were equally treated.  
Regulatory T cells and lymphocyte migration into intestinal tumors 
26 
 
 DT administration schedule.  Figure 7.
Day 3 after the first DT injection, 95% of Tregs in blood were depleted. 
However, Tregs are rapidly reappearing, demanding several injections to 
reduce the frequencies of Tregs but within two weeks, Treg frequencies 
are back to baseline and no efficient depletion can occur because of 
outgrowth of transgene negative FoxP3+ Treg (Figure. 8).   
 
 Treg frequencies during DT treatment in blood, MLN and tumor tissue.  Figure 8.
Adoptive transfer 
To examine the migration of lymphocytes in an in vivo system, 
Carboxyfluorescein succinimidyl ester (CFSE) labelled lymphocytes were 
injected into mice tail vein. For investigating specifically CXCR3 
migration, both anti-CXCR3 treated lymphocytes and untreated cells 
were labelled with either CFSE or FARred and co-injected into the tail. 
After two days the mice were sacrificed and migrated cells were identified 
with FC analysis. This method was used in paper II and III to investigate 
lymphocyte migration into murine intestinal tumors. 
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Intestinal lymphocyte isolation 
For investigation of the immune cells in tumors and normal tissue, the 
intestine needs to be digested to create a cell suspension. This was 
conducted by EDTA treatment to remove epithelial cells followed by 
collagenase treatment for LP or tumor digestion to yield a single cell 
suspension. The cells were counted and used for FC analyses or 
stimulation assays in all three papers. 
Human sample collection 
Human samples were collected during curative surgery from patients 
previously diagnosed with colon cancer with the permission of the 
Regional Research Ethics Committee of West Sweden and all patients 
gave an informed consent. None of the patients had undergone 
radiotherapy or chemotherapy for at least 3 years prior to colectomy, and 
none suffered from autoimmune diseases. Single cell suspensions were 
prepared by collagenase/DNase enzymatic digestion after removal of 
epithelial cells and used for FC analysis (paper III).  
Treg suppression assay 
To evaluate Treg suppressive capacity a co-culture system is the usual 
approach. By isolating Tregs from either mouse spleen in Paper II or 
from human peripheral blood in Paper III their suppressive capacity on 
target cells can be examined. In Paper II, Tregs were cultured together 
with conventional T cells and irradiated APCs to study suppression of 
effector T cells. After 3 days of culture, proliferation was measured by 
thymidine incorporation. In Paper III, we investigated if Treg directly 
affects endothelial production of CXCR3 ligands.  Human peripheral 
blood was used to isolate Tregs, which were cultured together with 
human umbilical vein endothelial cells (HUVEC). Culture media was 
analysed for secreted CXCL9, 10 and 11 by multiplex analyses.  
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Flow cytometry 
FC enables recognition of antigens either on cell surfaces or intracellular 
through cell permeabilisation by antigen-binding to fluorescence tagged 
antibodies. Cells are suspended in a stream of fluid and beamed by lasers 
at different wavelength. By detection of emitted light of different 
wavelengths from the cell the antibody can be identified. In this thesis 
cells prepared from spleen, MLN, blood, peripheral lymph node (paper I 
& III), intestine and tumors (paper I, II and III) were used to identify 
lymphocyte subsets, chemokine receptors, selectins, cytokine production, 
activation stage and cytotoxicity.  
PrimeFlow® RNA assay was used in Paper III to determine the source of 
CXCL10 production. This method allows FC analysis of RNA transcripts 
in single cells when FC antibodies are not available. This is a unique 
approach to RNA detection and signal amplification by amplifying the 
reporter signal rather than the target sequence, as usually done by PCR. 
The assay is conducted by addition of target specific probes that 
hybridize to the target RNA transcript in fixed cells. Signal amplification 
and binding with fluorescence-labelled probes allows the RNA transcript 
to be detected by flow cytometry.  
Immunofluorescence 
Distribution of cells in the intestinal tissue can be visualized by 
fluorescence microscopy. The intestine is embedded and sectioned into 
thin sections. Thereafter antigens of interest are labelled with a primary 
antibody followed by a secondary antibody carrying a fluorochrome. In 
this thesis, immunofluorescence (IF) was used to examine the 
distribution of T cells and adhesion molecules within tumor and intestine 
in both humans and mice (paper I and II).   
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Real time PCR 
Real time (RT) PCR is a common method to quantify gene expression at 
the RNA level. cDNA prepared from RNA in tissue lysates are amplified 
each thermal cycle by polymerase reactions. Fluorescence signals are sent 
out each cycle and while in the beginning the fluorescence is too low to 
be detected, at a certain point enough amplified products accumulate to 
yield a detectable signal. The cycle that gives rise to this signal gives a 
semi quantitative number on the amount of mRNA from a certain gene 
of interest, compared between samples. In paper I, II and III RT-PCR 
was used to examine expression of adhesion molecules, chemokines and 
cytokines.  
Multiplex analyses for protein detection 
In this thesis mRNA expression levels have been complemented by 
investigating protein levels in tissue by multiplex analyses. Cytokine 
secretion into culture media has also been determined in the same type of 
assay. In multiplex analysis, analytes of interest bind to beads pre-coated 
with analyte-specific capture antibodies. Through adding detection 
antibodies and a flourochrome the beads can be analysed on a dual-laser 
flow-based detection instrument. Several different analytes in the same 
suspension can be measured at the same time since the first laser 
classifies the bead and the second determines the magnitude of the 
flurochrome signal. This method has been used to quantify cytokine and 
chemokine levels in intestinal tissue (Paper II) and culture media (Paper 
III).  
Statistics 
To evaluate significant differences between organs or treatment groups 
Mann-Whitney test was used. Since we had relatively small sample groups 
and a non-normally distribution we choose non-parametric tests. p values 
<0.05 were considered significant.  
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RESULTS AND DISCUSSION 
In this thesis an extensive attempt has been conducted in order to 
investigate both APCmin/+ mice as a model for CRC and to determine the 
effect of Treg on lymphocyte migration in CRC. Several interesting 
findings have been made during this study, as summarized in this chapter.  
APCmin/+ mice exhibit similar immunological 
properties as WT mice 
To investigate CRC in an in vivo system we used APCmin/+ mice, a mouse 
model of spontaneous intestinal cancer. These mice have a mutated apc 
gene leading to tumor formation due to uncontrolled wnt signalling. The 
wnt signalling pathway has also been implicated in other biological 
systems, such as development of haematopoietic and lymphoid cells195,201-
203. To be able to use APCmin/+ mice as a model for CRC and to rule out 
the possibility that the apc mutation and increased adenoma formation 
affects systemic migration and immune cell frequencies, the peripheral 
immune cell composition was examined. When comparing WT mice with 
APCmin/+ mice at different ages, no differences were found between 
frequencies of T cells, Tregs and activated T cells in lymph nodes, spleen 
and blood (Paper I, Figure 1). This concludes that the systemic immune 
system remains largely intact regardless of age and increased tumor load 
and that the apc mutation does not influence the peripheral immune 
system and therefore is APCmin/+ mice suitable to use as a model for 
intestinal tumors.  
Treg in APCmin/+ mice supress conventional T cells 
equally well as Treg from WT mice 
As investigations of Treg activity in tumor-bearing mice was one of the 
major objectives of these studies, the suppressive capacity of Treg from 
APCmin/+ mice was investigated. A co-culture system was established were 
Tregs were cultured together with equal numbers of conventional T cells 
and irradiated APCs and T cell stimulation. Tregs from both APCmin/+ 
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mice and WT mice were able to supress proliferation in a similar manner, 
regardless of age and tumor load (Paper II, Figure 1). This concludes that 
Tregs in the APCmin/+ mice are still able to supress an immune response 
to the same extent as Tregs from WT mice.  
 Effect on T cell cytokine secretion by Treg from APCmin/+ mice and WT Figure 9.
controls. Splenic CD4+CD25- T cells from WT mice were isolated and cultured with 
anti-CD3 and antigen-presenting cells alone (grey bars) with APCMin/+ (black bars) or 
WT Treg (white bars) at 10, 14, 18, and 22 weeks for 3 days, n=2-6/time point. 
Supernatant cytokine concentrations were measured by multiplex assay. Bars represent 
mean and SEM. 
Co-culture experiments further revealed that Treg from both WT or 
APCmin/+ mice suppressed IFN-γ and TNF-α secretion from WT 
responder cells equally well, while they had no effect on IL-13 secretion 
(Figure 9) or IL-10 (data not shown). In contrast, IL-17A secretion was 
actually increased in the presence of Treg (Figure 9). Isolated APCmin/+ 
Treg alone secreted some IL-17A (108± 124 pg/ml) after stimulation, but 
these levels do not account for the whole increase detected in co-cultures, 
and IL-17A levels may have been influenced by the suppression of IFN-γ 
in the co-cultures. IFN-γ, TNF-α, IL-10 and IL-13 levels were low or 
undetectable in all cultures of Treg alone (data not shown).  
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It is interesting to note that the presence of Treg clearly increased the 
secretion of IL-17A in in vitro cell cultures, as IL-17 has been 
demonstrated to promote tumorigenesis in APCmin/+mice199,204. Also in 
humans, infiltration of Th17 cells into colon tumors predicts a poor 
outcome148. Th17 cells may enhance tumor growth by angiogenic effects, 
and by expression of the adenosine-generating ectonucleotidases CD39 
and CD73205. Further, it has been suggested that CD4+FoxP3+ putative 
Treg in APCmin/+ tumors secrete IL-17 but lack the IL-10 production seen 
in WT intestinal Treg. The shifted IL-17/IL-10 balance promoted mast 
cell accumulation and thereby tumor progression164. Adoptive transfer of 
WT Treg to APCmin/+ mice delayed tumor formation and also induced 
apoptosis in established tumors in the intestine, an effect that was 
dependent on IL-10164,206. Thus, a shift in Treg phenotype from IL-10 to 
IL-17 secreting cells during the course of tumorigenesis was predicted, 
and would indicate that tumor infiltrating Tregs in APCmin/+ mice have 
the ability to suppress Th1 responses and promote tumor progression 
due to on the cytokines secreted. Indeed, APCmin/+ Tregs suppressed 
production of the Th1 cytokines IFN-γ and TNF-α in vitro and promote 
IL-17 secretion. 
Higher frequencies of Treg in tumors of APCmin/+ mice  
After stating that the apc mutation does not affect the peripheral 
distribution of lymphocytes or Treg suppression and thus that the 
APCmin/+ model can be used to study the immune response in intestinal 
tumors, we directed our interest to the tumors to evaluate the 
intratumoral immune reactions. The mice show established tumors 
around 15 weeks of age and after 20 weeks the tumors are often large and 
prevent the passage of food leading to death. However, differences exist 
between animal facilities depending on inflammation and bacterial flora. 
We chose to investigate the tumors at 18 weeks of age, at which time we 
collected the intestine and used both tumors and unaffected intestinal 
tissue for FC, RT-PCR and IF examination.  
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The cell composition in the tumor was evaluated and lower frequencies 
of conventional T cells were found in tumors compared to surrounding 
unaffected tissue (Paper I, Figure 2). The tumor microenvironment can 
be hostile to T cells and their effector functions due to presence of 
enzymes that depletes the amino acids tryptophan and arginine, high 
concentration of tumor secreted lactate and accumulation of suppressive 
cells such as Treg207. TIL are crucial for anti-tumor immunity151,152, high 
frequencies of CD3+ and CD8+ cells in tumor tissues have been 
correlated to positive clinical outcome208,209. The decrease of T cells in 
tumors of the APCmin/+ mice indicates that intestinal tumors are able to 
affect the immune system in order to avoid an anti-tumor response.  
Tumors of the APCmin/+ mice had a higher frequency of Treg compared 
to unaffected tissue (Paper I, Figure 4) and this could be one reason for 
the decreased conventional T cell numbers. Treg could decrease the 
number of conventional T cells through several mechanisms, such as IL-
2 consumption, cytolysis and cytokine secretion210. Tumors are able to 
accumulate Tregs and this would then help them evade an anti-tumor 
attack211. 
Altered chemokine expression in APCmin/+ mice 
A shift in the lymphocyte composition in the intestinal tumors may result 
from altered recruitment mechanisms. Therefore, chemokines and their 
receptors important for T cell migration were investigated (Figure 10 and 
Paper I, Figure 5). CCL17, which attracts CCR4+ Tregs and effector T 
cells212, was significantly up-regulated in tumors of APCmin/+  mice 
compared with unaffected tissue. There was also a trend of higher levels 
of CCL22, another CCR4 ligand, in the tumors although this was not 
significant.  The expression of CCR4 by Tregs and conventional T cells 
were however similar when comparing tumor and unaffected tissue 
indicating that the increase of CCR4 ligands in tumors is not sufficient to 
increase effector T cell migration.  
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 Chemokine receptor expression by conventional T cells in LP and tumors Figure 10.
of APCmin/+ mice. 
Liu et al. have shown that increased levels of CCR6 expression are 
responsible for accumulation of Treg in an N-methyl-N-nitrosourea and 
Helicobacter pylori induced CRC mouse model213. In their model, almost all 
tumor infiltrating Treg expressed CCR6 and interaction with the ligand 
CCL20 was the mechanism behind their increased Treg infiltration. 
However, the level of CCL20 was unchanged in tumors compared to 
normal tissue in our APCmin/+ mice (Paper I, Figure 5), but Tregs did 
express higher levels of CCR6 in the tumors of APCmin/+ mouse (Paper I, 
Figure 5) and this might be one mechanism for Treg infiltration into 
tumor tissue.  
The intestinal chemokine CCL25 is produced by intestinal epithelial 
cells108 and is crucial for T cell recruitment to intestinal LP. Intestinal 
APCmin/+ tumors produced less CCL25 than unaffected tissue (Paper I, 
Figure 5). This is in analogy with another epithelial mucosal chemokine, 
CCL28, which is also produced in lower amounts in human colon 
adenocarcinomas then unaffected tissue214. The lack of CCL25 may 
benefit the tumor by reducing recruitment of effector lymphocytes to the 
tumor but also by allowing extra intestinal metastasis of CCR9+ tumor 
cells. As recently demonstrated by Chen et al.109, CCR9-CCL25 interaction 
prevent the spread of colon cancer cells from the intestine, and therefore, 
reduced CCL25 levels would be a mechanism for the tumors to 
metastasize and leave the primary tumor. The expression of CCR9 on 
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infiltrating T cells (Paper I, Figure 5) was however not changed between 
tumor and unaffected tissue in the APCmin/+mice.   
Tumor associated Tregs expressed lower levels of CXCR3 than Tregs in 
the unaffected tissue, indicating that this chemokine is not accountable 
for Treg accumulation in tumors (Paper I, Figure 5). Instead, Treg 
express CCR9, although the chemokine ligand was not increased. 
Therefore, Treg could have used CCR6 to enter the tumors and 
accumulate in the tissue. Overall, several changes in expression of 
chemokine and chemokine receptors were observed between intestinal 
tumor and unaffected tissue and this could be accountable for the 
changes in tumor immune cell composition.  
Increased frequencies of Treg in human intestinal 
adenoma  
Human adenomas, which mainly correspond to the tumors in our 
APCmin/+ mice, have not been examined to the same extent as invasive 
CRC. To investigate if the APCmin/+ mouse model for intestinal tumors 
corresponds to human adenomas, the T cell composition in human 
intestinal adenomas was investigated by IF. Already in this early tumor 
formation stage, an accumulation of Treg was found (Figure 11 and 
Paper I, Figure 4). However, the increased Treg frequencies did not affect 
the adenoma frequencies of conventional T cells, which remained 
unchanged compared to unaffected intestinal tissue (Figure 11). 
A decrease in the expression of the adhesion molecule MAdCAM-1 was 
observed in human adenomas (Figure 11) but a corresponding decrease 
was not found in the APCmin/+ mice. In later stages of CRC a decrease of 
MAdCAM-1 has previously been documented by our group215 and this 
new finding demonstrates that this decrease is consistent throughout the 
adenoma CRC progression and indicates a difference in lymphocyte 
homing mechanisms to intestinal malignancies between mice and human.  
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 T cells frequencies and MAdCAM-1 expression in human intestinal Figure 11.
adenomas and unaffected LP.  
Depletion of Treg in APCmin/+ mice leads to increased 
frequencies of conventional T cells 
In order to investigate the function of Treg in intestinal tumors we 
introduced the DEREG mice and bred them together with APCmin/+ mice 
to generate APCmin/+/DEREG mice. This allowed us to selectively 
deplete Treg by DT injections and study the impact on the immune cell 
composition in intestinal tumors.  
An accumulation of conventional T cells was found after Treg depletion 
in the intestinal tumors. This was true for both CD4+ and CD8+ T cells 
examined with IF and FC (Paper II, Figure 2). Accumulation of Treg is 
thereby one mechanism tumors use to decrease the frequencies of 
conventional T cells in the tumor. By suppression of a potent anti-tumor 
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response Treg can contribute to tumor progression. Previously, increased 
T cell frequencies have been observed in experimental thymomas, 
melonoma and chemically induced sarcomas after Treg depletion and 
these new data for spontaneous intestinal tumors are in line with these 
findings216-218.  
By using the crossing of APCmin/+ mice with DEREG we reach at least 
90% depletion of Treg, which is sufficient to gain an increased T cell 
frequency in tumors. Other studies using a CD25 antibody only achieved 
a 70% Treg depletion and no differences in lymphocyte numbers, 
indicating that even in low numbers Treg are strong enough to reduce 
lymphocyte accumulation219. 
Increased T cell proliferation and migration after 
Treg depletion 
The increased frequency of conventional T cells may have different 
causes, such as increased migration into the tumor, increased local 
proliferation or that the T cells are less prone to leave the tumor. 
Therefor we aimed to study some of these potential causes. An increased 
proliferation of conventional T cells was observed in the tumor after 
Treg depletion, based on expression of Ki67 (Paper II, Figure 7). This 
would partly contribute to the increased frequency of conventional T 
cells seen in Treg depleted tumors.  
Furthermore, migration was studied through adoptive transfer 
experiments where CFSE labelled MLN cells were injected into Treg 
depleted APC/min+/DEREG mice and control APC/min+ mice. After Treg 
depletion more lymphocytes migrate into the tumors (Paper III, Figure 1) 
and that confirms that Treg also prevent migration into the tumor. This is 
in line with previous studies in our group were human Tregs inhibited 
transendothelial migration in an in vitro system92. Furthermore, a specific 
increase of CD4+ and CD8+ T cell migration into tumors was seen in the 
adoptive transfer experiments (Paper III, Figure 1) stating that Treg 
specifically reduce migration of effector T cells. However, the T cells 
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migrating into Treg depleted tumors were not more active or proliferative 
then cells migrating into Treg sufficient tumors (Paper III, Figure 6) 
indicating that activation of T cells may occur in the tumors by intra-
tumoral antigen-presenting cells, rather than in the draining lymph nodes.  
Depletion of Treg leads to a Th1-associated cell 
infiltration  
To define the mechanisms behind the increased migration several 
important chemokines and chemokine receptors for T cell migration 
were investigated. Of great interest, CXCR3, which is associated with a 
Th1 cell response, was significantly higher on conventional T cells in 
Treg depleted tumors than Treg sufficient tumors (Paper II, Figure 4). 
This also corresponded to a higher expression of the CXCR3 ligands, 
CXCL9 and CXCL10 in Treg depleted tumors (Paper II, Figure 3). 
Besides attracting effector T cells, CXCL10 has anti-tumor potential by 
reducing angiogenesis through inhibiting proliferation of endothelial cells 
and inducing apoptosis of cancer cells220 thus reducing tumor growth. In 
CRC higher expression of CXCR3 ligands is associated with increased 
TIL accumulation and patient survival221-223.  Tumor promoting effects of 
CXCR3 ligands have also been observed in several other cancer types224, 
and this can possibly be explained by metastasis of CXCR3+ tumor cells 
or tumor infiltration of suppressive CXCR3+ Tregs.   
Several different cell types in the intestine of APCmin/+ mice, T cells, 
monocytes and epithelial cells produce CXCR3 ligands (Paper III, Figure 
4). However, after Treg depletion, only endothelial cells increase their 
expression of CXCL10 in intestinal tumors, possibly highlighting them as 
targets for Treg suppression to reduce an anti-tumor response. This is a 
possibility that we will address in future studies.  
The Th1 associated cytokine IFN-γ was increased in tumor tissue after 
Treg depletion (Paper II, Figure 5). IFN-γ is crucial for anti-tumor 
immunity. For example, Zhang et al. have demonstrated that APCmin/+ 
mice lacking IFN-γ had a more severe tumor progression, which could 
Regulatory T cells and lymphocyte migration into intestinal tumors 
40 
possibly lead to an invasive carcinoma225. Other studies have also pointed 
out the possible anti-tumor effects of IFN-γ by inducing T cell 
proliferation226,227, upregulate MHC expression on tumor cells157 and 
blocking of angiogenesis228,229.  
Altogether, an increased expression of CXCR3 on tumor infiltrating T 
cells, higher secretion of its ligands CXCL9 and 10 specifically in the 
tumors and increased IFN-γ levels indicates that when Treg are depleted 
a Th1 associated response is reinstated which could lead to an anti-tumor 
response.  
CXCR3 is crucial for intestinal migration  
Chemokines guide lymphocytes into tissues and may be responsible for 
the increased T cell migration. We reasoned that CXCR3-mediated 
chemotaxis may be an important mean of T cell recruitment into 
intestinal tumors as Treg depletion increased the production of CXCL9 
and CXCL10 selectively in the tumors. Therefore, we examined the effect 
of CXCR3 blocking on lymphocyte migration into APCmin/+ tumors in an 
adoptive transfer system. The small molecule CXCR3 antagonist 
AMG487, was used for blocking CXCR3171.  This CXCR3 blocking agent 
has been used in clinical trials230, since it is shown to inhibit Th1 cell 
migration into sites of inflammation231. However, a phase II trial was 
halted due to lack of efficacy in treating psoriasis232. In tumor mouse 
models of breast cancer233 and CRC234, the CXCR3 antagonist has been 
used to study lung metastasis of CXCR3+ tumor cells.  
Pre-treatment of lymphocytes with the specific CXCR3 antagonist 
AMG487233 before transfer potently reduced lymphocyte migration into 
both small intestine and tumor in our APC/min+ mice (Paper III, Figure 3). 
Furthermore, CD4+ T cells had an even more profound CXCR3 mediated 
migration into tumors. Li et al. show that increased frequencies of 
CXCR3+ T cells in the tumors is associated with prolonged survival in 
gastric cancer235, indicating the importance of CXCR3 mediated migration 
into tumors. 
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Human CRC immunological composition 
To verify some of the mouse model data in human CRC, Treg 
frequencies and chemokine composition was investigated. An increase of 
Tregs examined by RT-PCR was found in the tumors compared to 
surrounding unaffected tissue (Figure 12), which confirms our previous 
FC analysis215. An increased Treg accumulation in tumors has also been 
observed in other mouse and human studies160,164,215,236.  
                   
 Relative expression of FOXP3+ mRNA in human CRC and unaffected Figure 12.
tissue.  
In invasive CRC, an increase of the CXCR3 ligands CXCL9, 10 and 11 
was observed (Paper III, Supplementary figure 2). Furthermore, several 
different cell types such as T cells, monocytes and endothelial cells 
produced these ligands (Figure 13 and Paper III, Figure 5) confirming 
our data from the APC/min+ mouse model.  
 
 Human cells expressing CXCR3 ligands in colon tumors and unaffected Figure 13.
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An increase of CXCR3 ligands has been observed in several cancer types 
such as basal cell carcinoma237, ovarian cancer238, B-cell lymphoma239 and 
melanoma240, and has been postulated to contribute to tumor growth. 
Human colon cancer cells express the CXCR3-B isoform241, which has 
growth-inhibitory properties and inhibits chemotaxis105. Over-production 
of CXCR3 ligands can lead to a down regulation of CXCR3-B, thus 
promoting tumor growth and metastasis242. By this mechanism advanced 
CRC may possibly secrete CXCR3 ligands in an autocrine manner, in 
order to grow and may not affect CXCR3 mediated lymphocyte 
infiltration. Actually, a decrease of CXCR3+ T cell frequencies have been 
observed in CRC compared to the unaffected mucosa215 thus 
strengthening the concept that the increase of CXCR3 ligands do not 
affect lymphocyte infiltration but tumor progression in invasive CRC.  
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CONCLUSION                                        
AND FUTURE PERSPECTIVES 
 
 Treg hinders an anti-tumor response. In this thesis Treg suppressive Figure 14.
capacity on several different anti-tumor mechanisms have been examined. Treg can both 
inhibit migration and proliferation of effector T cells. Furthermore, Treg decrease 
secretion of CXCL9 and 10 thereby hindering migration of CXCR3+ T cells. Also 
secretions of cytokines are affected. Altogether this indicates that Treg hinders an 
effective Th1 associated immune response against tumor cells.  
This thesis postulates that Treg are able to reduce an anti-tumor response 
through several different mechanisms that ultimately diminishes the 
amount of effector T cells in the intestinal tumor tissue (Figure 14). The 
APCmin/+ mouse model of intestinal tumors was used for this work since 
we could show that the apc mutation manifest immunological changes 
specifically in the tumors. Through depletion experiments the 
consequence of a Treg deficient tumor environment has been thoroughly 
examined and formed our proposition. In particular, Treg reduces a Th1 
response, as demonstrated by lower levels of IFN-γ, CXCR3+ T cells and 
decreased T cell migration. The Th1 associated chemokine receptor 
CXCR3 was shown to be specifically important for migration into the 
tumor tissue. After Treg depletion the CXCR3 ligands CXCL9 and 10 
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were increased in the tumor tissue and specifically endothelial cells 
increased their ligand production indicating that Treg may reduce 
chemokine signalling to hinder an effective anti-tumor response. A Th1 
response is particularly beneficial in tumor regression since it activates 
CTL and NK cells, which both can attack cancer cells and defend against 
tumor progression243. Furthermore, a strong Th1 response has been 
correlated to improved anti-tumor response and overall patient 
survival147,148,155,211,244. In CRC, reduced levels of both Th1 cells and their 
cytokines have been observed in several studies indicating a suppressive 
milieu for an anti-tumor response245-249. Therefore, Treg blocking could 
be a treatment that may reduce intestinal tumor development by 
accumulation of a Th1 response.  
Today several Treg depletion studies have been conducted in both 
human and mice by targeting CD25 with anti-CD25 mAbs or IL-2-toxin 
fusion proteins216,218,250-253. In some studies tumor regression have been 
observed following Treg depletion216,254. However, these strategies also 
affect activated CD25+ effector T cells thereby limiting a positive effect. 
Other Treg depletion strategies have involved affecting Treg function by 
blocking of CTLA-4255,256, OX-40 a co-stimulatory molecule of the TNF 
receptor family257 and GITR258, which all have resulted in an increased 
anti-tumor response, strengthen the concept of Treg suppressive capacity 
of an anti-tumor response. However, Treg depletion is also usually 
accompanied by autoimmune reactions, thereby limiting its usefulness.  
Treg depletion has not been extensively investigated in intestinal tumors 
and in our short-term Treg depletion protocol no effect on tumor size 
was observed.  DEREG mice outgrow transgene negative Treg, not 
susceptible to DT depletion200, and can not be used for long term 
experiments. Possibly only a short-term Treg depletion is not sufficient to 
affect tumor size in the APCmin/+ mice. However, it can also indicate that 
Treg depletion as a single treatment is not effective enough in intestinal 
tumors and other strategies might be needed. 
PD-1 is an inhibitory immune receptor up-regulated on T cells after 
activation. Tumors can express PD-L1 to create an immunosuppressive 
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milieu for T cells227 thereby preventing an immune response. Peng et al, 
have shown that through blocking of PD-1, both CXCL10 and IFN-γ 
increased at the tumor site without decreasing Treg frequencies227. Several 
clinical trials conducted with PD-1 monoclonal antibodies to treat cancer 
have nevertheless had a relatively low complete response rate140,259,260. 
However, Treg in intestinal tumors manifest a higher suppressive capacity 
by e.g. higher expression of PD-L1, CD39 and CTLA-4 (Ahlmanner et al, 
unpublished). Perhaps blocking of only PD-1 is not efficient since Treg 
still can exert an immunosuppressive effect on T cells. This implies a 
need for dual treatments. By depleting Treg we may be able to increase 
migrating T cells but due to other immunosuppressive mechanism from 
tumor cells a joint strategy to both inhibit the immunosuppressive milieu 
in the tumor by PD-1 or PD-L1 inhibition together with Treg depletion 
may be a viable strategy for tumor regression.  
Another possible mechanism for tumor regression could be to increase 
the availability of CXCR3 ligands locally in the tumors to optimize 
migration of effector T cells into the tumors. In breast cancer and ovarian 
cancer models, suppression of endogenous PGE2 synthesis by 
cyclooxygenase has been shown to reduce tumor growth through 
increase of intratumoral CXCR3 ligands and increased Th1 responses261-
263. Also transfections of the IL-12 gene in a model of head and neck 
cancer up-regulated CXCL9 expression264. However, both Treg and 
cancer cells express CXCR3241 and this might not be an effective single 
treatment since it could increase Treg accumulation and tumor 
metastasis. But combining promotion of CXCR3 ligands with Treg 
depletion might be an effective way to increase an immune response 
against tumor progression.  
Intestinal cancer is an increasing disease in the western world and is still a 
major obstacle to be dealt with.  Hopefully this thesis will help elucidate 
one hurdle the anti-tumor immune system has to overcome, namely the 
Treg. By transiently eliminating Treg or modulating their effector 
functions there might be an opportunity for tumor regression.   
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